C M McGarry

  • Citations Per Year
Learn More
3623 Background: Capecitabine (CAP) and irinotecan (IR) are used in the treatment of colorectal cancer (CRC). SN-38, the active metabolite of IR, is metabolized by several UDP-glucuronosyltransferases including UGT1A1, UGT1A6, and UGT1A7. Although UGT1A1 genotype has previously been correlated with IR toxicity, the association between other UGT genotypes(More)
In vivo models in rodents and primates were used to investigate ways of overcoming the poor oral and rectal absorption of ceftriaxone. The sodium salt of ceftriaxone at 20 mg/kg was formulated in C8-C10 chain length, mono- and diglyceride extracts of coconut oil (Capmul) and administered intraduodenally to adult rats. Peak plasma levels of 17-52(More)
The dual-action antibacterial R 23-9424 (desacetylcefotaxime linked to the quinolone fleroxacin) is a new antibacterial agent with excellent in vitro activity. It was evaluated for in vivo efficacy in comparison with the cephalosporin cefotaxime and the quinolone component, fleroxacin. Ro 23-9424 demonstrated significant activity against all strains tested(More)
Ro 24-4383 contains desacetylcefotaxime linked by a carbamate bond at the 3' position to ciprofloxacin. Ro 24-4383 was active against 99% of the 363 gram-positive and gram-negative aerobes tested in vitro, while the comparative agents cefotaxime and ciprofloxacin were active against 77 and 97%, respectively. The activities (ED50: mg/kg s.c.) of Ro 24-4383,(More)
  • 1